English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Relationship between imaging biomarkers, age, progression and symptom severity in Alzheimer's disease

MPS-Authors
/persons/resource/persons19621

Dukart,  Jürgen
Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society;
Laboratoire de Recherche en Neuroimagerie (LREN), Centre hospitalier universitaire vaudois, Lausanne, Switzerland;
Leipzig Research Center for Civilization Diseases (LIFE), University of Leipzig, Germany;
Berlin School of Mind and Brain, Humboldt University Berlin, Germany;

/persons/resource/persons19872

Mueller,  Karsten
Methods and Development Unit Nuclear Magnetic Resonance, MPI for Human Cognitive and Brain Sciences, Max Planck Society;

/persons/resource/persons20065

Villringer,  Arno
Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society;
Leipzig Research Center for Civilization Diseases (LIFE), University of Leipzig, Germany;
Clinic for Cognitive Neurology, University of Leipzig, Germany;

/persons/resource/persons19981

Schroeter,  Matthias L.
Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society;
Leipzig Research Center for Civilization Diseases (LIFE), University of Leipzig, Germany;
Clinic for Cognitive Neurology, University of Leipzig, Germany;

External Resource
No external resources are shared
Fulltext (public)

Dukart_Mueller_2013.pdf
(Publisher version), 2MB

Supplementary Material (public)
There is no public supplementary material available
Citation

Dukart, J., Mueller, K., Villringer, A., Kherif, F., Draganski, B., Frackowiak, R., et al. (2013). Relationship between imaging biomarkers, age, progression and symptom severity in Alzheimer's disease. NeuroImage: Clinical, 3, 84-94. doi:10.1016/j.nicl.2013.07.005.


Cite as: http://hdl.handle.net/11858/00-001M-0000-0014-79AD-B
Abstract
The early diagnostic value of glucose hypometabolism and atrophy as potential neuroimaging biomarkers of mild cognitive impairment (MCI) and Alzheimer's disease (AD) have been extensively explored using [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) and structural magnetic resonance imaging (MRI). The vast majority of previous imaging studies neglected the effects of single factors, such as age, symptom severity or time to conversion in MCI thus limiting generalisability of results across studies. Here, we investigated the impact of these factors on metabolic and structural differences. FDG-PET and MRI data from AD patients (n = 80), MCI converters (n = 65) and MCI non-converters (n = 64) were compared to data of healthy subjects (n = 79). All patient groups were split into subgroups by age, time to conversion (for MCI), or symptom severity and compared to the control group. AD patients showed a strongly age-dependent pattern, with younger patients showing significantly more extensive reductions in gray matter volume and glucose utilisation. In the MCI converter group, the amount of glucose utilisation reduction was linked to the time to conversion but not to atrophy. Our findings indicate that FDG-PET might be more closely linked to future cognitive decline whilst MRI being more closely related to the current cognitive state reflects potentially irreversible damage.